Tag Archives: NASDAQ:SAGE

SAGE Therapeutics (SAGE) Receives a Hold from Mizuho Securities

In a report released today, Vamil Divan from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $36.00. The company’s shares closed last Tuesday at $29.03, close to its 52-week low

H.C. Wainwright Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

In a report issued on March 19, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $78.00. The company’s shares closed last Monday at $26.60, close to its

Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (NASDAQ: SAGE) and Hookipa Pharma (NASDAQ: HOOK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE – Research Report) and Hookipa Pharma (HOOK – Research Report). SAGE Therapeutics (SAGE) Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a

Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

Mizuho Securities analyst Vamil Divan maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $58.00. The company’s shares closed last Monday at $42.30, close to its 52-week low of $42.05. According

SAGE Therapeutics (SAGE) Gets a Hold Rating from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $78.00. The company’s shares closed last Monday at $52.01, close to its 52-week low

Ladenburg Thalmann & Co. Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $52.00. The company’s shares closed last Monday at $52.01, close to its 52-week low of